Nat Rev Cancer,2005,5.Kras mutations as anindependent prognosticfactorin patients with advanced colorectal cancer treated with cetuximab .Phase1study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurementsin patients with relapsed or ......